Clinical performance and cost analysis of different screening strategies for CIN2+ and CIN3+ diagnoses after 3 years follow-up
| Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Colposcopy referral rate (%) | NNR* | |
| ≥CIN2 | ||||||
| Strategy 1 | 95.9 (90.1 to 100.0) | 86.8 (85.7 to 88.0) | 10.2 (9.2 to 11.2) | 99.9 (99.7 to 100.0) | 7.8 (6.8 to 8.7) | 9.8 (8.9 to 10.9) |
| Strategy 2 | 48.0 (34.2 to 61.8) | 90.4 (89.3 to 91.4) | 7.3 (5.5 to 9.7) | 99.1 (98.8 to 99.3) | 9.4 (8.4 to 10.4) | 13.7 (10.3 to 18.2) |
| Strategy 3 | 98.0 (94.0 to 100.0) | 79.8 (78.4 to 81.2) | 7.0 (6.5 to 7.5) | 99.9 (99.7 to 100.0) | 11.9 (10.8 to 13.0) | 14.3 (13.3 to 15.4) |
| ≥CIN3 | ||||||
| Strategy 1 | 100.0 (100.0 to 100.0) | 86.4 (85.2 to 87.5) | 6.3 (5.8 to 6.8) | 100.0 (100.0 to 100.0) | 7.8 (6.8 to 8.7) | 15.9 (14.7 to 17.2) |
| Strategy 2 | 56.7 (38.9 to 74.4) | 90.2 (89.2 to 91.2) | 5.2 (3.8 to 7.1) | 99.5 (99.3 to 99.7) | 9.4 (8.4 to 10.4) | 19.2 (14.1 to 26.3) |
| Strategy 3 | 100.0 (100.0 to 100.0) | 79.3 (77.9 to 80.7) | 4.2 (4.0 to 4.5) | 100.0 (100.0 to 100.0) | 11.9 (10.8 to 13.0) | 23.8 (22.2 to 25.0) |
CIN, cervical intraepithelial neoplasia; NNR, the number of performed colposcopies to detect one case; NPV, negative predictive value; PPV, positive predictive value.